Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Recurrence 1Carcinoma, Transitional Cell 1

Interventions

toripalimab 4pembrolizumab 4Gemcitabine 4tislelizumab 2durvalumab 2Nivolumab 2Cisplatin 2Carboplatin 2AZD4547 2tipifarnib 1tesetaxel 1sapanisertib 1regorafenib 1pyrotinib 1nintedanib 1famitinib 1disitamab vedotin 1camrelizumab 1bintrafusp alfa protein, human 1atezolizumab 1anlotinib 1aldesleukin 1advexin 1Vitamin B 12 1Trastuzumab 1Taxes 1Surgical Procedures, Operative 1Saline Solution 1Resistance Training 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Transitional Cell × nintedanib × Clear all
NCT02278978 2015-05-12

BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma

National Taiwan University Hospital

Phase 2 Unknown
129 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡